Article
Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.
Clinical pharmacology and therapeutics - 1 Jun 2012
Sprowl J A, Gregorc V, Lazzari C, Mathijssen R H, Loos W J, Sparreboom A
Abstract excerpt
ABCC2 (MRP2, cMOAT) expression has been implicated in cisplatin resistance in vitro. In mice, cisplatin disposition and toxicity were unaffected by Abcc2 knockout (Abcc2−/−). Moreover, in cancer patients (n = 237), cisplatin pharmacokinetics (P > 0.12) and efficacy (P > 0.41) were not associated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
